Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aditxt, Inc.
< Previous
1
2
Next >
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
January 03, 2023
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials
October 21, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection
October 12, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health
October 07, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements
September 29, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering
September 27, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces Closing of $20.0 Million Public Offering
September 20, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022
September 13, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials
July 08, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore™ to Accelerate Adoption and Revenue Growth
April 14, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th
April 05, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt to Participate in the 2022 Virtual Growth Conference
March 23, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron
January 18, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25th-27th, 2022
January 14, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Provides Online Business Update Townhall Meeting with Amro Albanna, Co-Founder & CEO
January 12, 2022
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use
December 29, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt, Inc. Signs Non-Binding Letter of Intent to Acquire Point-of-Care Diagnostic Technology Development Company
December 13, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces Closing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants
December 06, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Extends the Timeline to Sign the Definitive Agreement to Acquire AiPharma Global to December 16, 2021
December 02, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces Pricing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants Led by Leading Healthcare Investor
December 01, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces Proposed Public Offering of Common Stock and Warrants
November 30, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
The Largest Law Enforcement Agency in the State of Kansas, Johnson County Sherriff’s Office, to Become First in the Nation to Deploy AditxtScore™ for Immune Scoring for its Employees and First Responders
November 22, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Webinar at 2pm ET to Explore PRESECO Results
November 12, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Provides an Update Regarding its Target Acquisition AiPharma Global Holdings LLC
November 12, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Partners With CLX Health to Offer AditxtScore™ for COVID-19 Immune Monitoring Service Through CLX’s TrustAssure™ Platform
November 03, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces Closing of $4.25 Million Public Offering
October 20, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt to Present at the Dawson James 6th Annual Small Cap Growth Conference in Florida on October 21, 2021
October 20, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Announces Pricing of $4.25 Million Public Offering
October 18, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt to Present at the LD Micro Main Event in Los Angeles on October 13, 2021
October 07, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
Aditxt Signs a Transaction Agreement to Acquire AiPharma, Rights Holder of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of Over 1.5 Million COVID-19 Patients Outside the U.S. and Canada
October 05, 2021
From
Aditxt, Inc.
Via
Business Wire
Tickers
ADTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.